Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.08
Price-0.80%
-$0.06
1Y
Price
Market Cap
$678.240m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-128.5%
EBITDA Margin-150.8%
Net Profit Margin-13.8%
Free Cash Flow MarginRevenue
$179.912m
+6.1%
1y CAGR-13.7%
3y CAGR-9.3%
5y CAGREarnings
-$102.160m
-734.2%
1y CAGR-205.7%
3y CAGR-178.0%
5y CAGREPS
-$1.31
-670.6%
1y CAGR-180.4%
3y CAGR-151.6%
5y CAGRBook Value
$186.432m
$472.625m
Assets$286.193m
Liabilities$196.924m
DebtDebt to Assets
41.7%
-2.7x
Debt to EBITDAFree Cash Flow
-$34.389m
+58.9%
1y CAGR+47.1%
3y CAGR-361.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company